[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"S. Andrea Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":95},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100658448","ai-assisted-3d-reconstruction-for-lung-resection-planning-100658448",false,"NCT07853157","AI-Assisted 3D Reconstruction for Lung Resection Planning","Prospective Validation of an Artificial Intelligence-Based 3D Reconstruction Model for Preoperative Planning of Lung Resection.","Inclusion Criteria:\n\n* Age ≥18 years\n* Scheduled for anatomical lung resection (segmentectomy, lobectomy, bilobectomy, or pneumonectomy)\n* Availability of a preoperative contrast-enhanced chest CT scan suitable for 3D reconstruction, with slice thickness ≤1.5 mm.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Preoperative CT images of insufficient quality or technical characteristics for 3D reconstruction.\n* Cancellation of the planned surgical procedure before surgery.\n* Inability or unwillingness to provide informed consent.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to validate an artificial intelligence (AI)-based system for automated three-dimensional (3D) reconstruction of pulmonary anatomy from preoperative chest computed tomography (CT) scans in patients undergoing lung resection.\n\nThe AI system will automatically identify and reconstruct relevant pulmonary anatomical structures, including pulmonary arteries, veins, bronchi, lobes, and segments. AI-generated 3D reconstructions will be compared with expert manual 3D reconstructions and with anatomical findings documented during surgery.\n\nThe primary objective is to assess the anatomical accuracy of AI-generated 3D reconstructions in identifying surgically relevant bronchovascular anatomy and anatomical variants. Secondary objectives include evaluating accuracy for individual anatomical structures, discrepancies between automated and manual reconstructions, concordance with intraoperative findings, and the time required to generate and review the automated reconstruction.\n\nThe study is observational and will not modify the planned surgical procedure or standard patient care.",[24,25,26],"Lung Cancer","Artifical Intelligence","Surgery for Primary Lung Cancer",[28,29,30,31,32,33,34],"Artificial Intelligence","Three-Dimensional Reconstruction","Lung Resection","Thoracic Surgery","Preoperative Planning","Pulmonary Anatomy","Image Segmentation","NOT_YET_RECRUITING","2026-09-23",{"date":38,"type":39},"2026-10-01","ACTUAL",{"date":41,"type":20},"2026-11-02",{"date":43,"type":20},"2027-08-01",{"name":45,"class":46},"S. Andrea Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":72,"locationsCount":47},"100353979","phase-2-bacille-calmette-gurin-bcg-vaccine-in-radiologically-isolated-syndrome-ris-100353979","NCT03888924","Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)","Inclusion Criteria:\n\n1. Male and female of any race and \\> 18 years old.\n2. Diagnosis of RIS (4) within the last five years.\n3. Signed Informed Consent.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation.\n2. Concomitant or previous use of immunosuppressive or immunomodulating treatment (except sporadic use of corticosteroids) within the last five years.\n3. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation. Such conditions may include cardiovascular, pulmonary, hepatic, renal, severe systemic mycotic infections, metabolic diseases or malignancies, primary or secondary immunodeficiencies as determined by medical history, physical exam, laboratory tests, chest X-ray, electrocardiogram (ECG), and Mantoux reaction.\n4. Any medical or psychiatric condition that may affect the subjects ability to give informed consent, or to complete the study, or if the subject is considered by the treating neurologist to be, for any other reason, an unsuitable candidate for this study.\n5. Subjects with inability to successfully undergo MRI scans.\n6. Concomitant radiotherapy.\n7. Known hypersensitivity to any component of the vaccine.\n8. Past bone marrow stem cell transplantation and organ transplantation.\n9. Other vaccinations in the previous 4 weeks.",{"count":55,"type":20},100,"INTERVENTIONAL",[58],"PHASE2","Multiple sclerosis (MS) witnessed relevant therapeutic progress in the last decade. Following the extraordinary progress in the treatment of relapsing-remitting (RR) multiple sclerosis (MS), two major unmet needs remain to be addressed by translational research in this field: progressive MS and the \"dream\" of a world free of MS. As far as the latter is concerned, the investigators can hope to make the dream come true by understanding the etiology of the disease and hence design definitive cures. A more realistic and pragmatic perspective may be the prevention of the clinical onset of the disease, a research field that promises to become increasingly important as the integration of genetic data with endophenotypes, magnetic resonance imaging and other biomarkers ameliorates the ability to predict the development of the disease under clinical circumstance. Bacille Calmette-Guerin (BCG) vaccine has been tested with encouraging results in early MS and clinically isolated syndrome (CIS). The knowledge that disease-modifying therapies work best when used early in the demyelinating process raises the question about whether to try this approach - which is safe, cheap and handy - in individuals with radiologically isolated syndrome (RIS).\n\nRadiologically isolated syndrome is a new entity, diagnosed when the unanticipated magnetic resonance imaging (MRI) finding of brain spatial dissemination of focal white matter (WM) lesions highly suggestive of MS occurs in subjects without symptoms of MS, and with normal neurological examinations. Conversion to clinically isolated syndromes (CIS) were described in 84% of RIS individuals with spinal cord lesions over a median time of 1.6 years from the date of the first MRI. Whether or not to treat this condition remains currently a clinical conundrum. Bacille Calmette-Guérin (BCG) vaccine may have these characteristics since it resulted beneficial in early MS and first demyelinating episodes. Being safe, cheap and handy, the investigators propose to investigate its use to prevent progression of the demyelinating process in radiologically isolated syndrome. An approach such as BCG vaccine seems appropriate as a front-line immunomodulatory approach for RIS people. In a pilot study BCG vaccine was safe and effective in reducing disease activity at MRI, and the risk of developing persistent T1-hypointense lesions ('black holes' -BH- expression of tissue damage) in subjects with MS.",[61],"Multiple Sclerosis",[63,64],"BCG Vaccine","Radiologically Isolated Syndrome","RECRUITING","2024-11-27",{"date":68,"type":39},"2024-11-29",{"date":70,"type":39},"2019-06-17",{"date":38,"type":20},{"name":45,"class":46},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":56,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":47},"100336476","phase-2-riluzole-in-patients-with-spinocerebellar-ataxia-type-7-100336476","NCT03660917","Riluzole in Patients With Spinocerebellar Ataxia Type 7","Riluzole in Patients With Spinocerebellar Ataxia Type 7: a Randomized , Double-blind, Placebo-controlled Pilot Trial With a Lead in Phase","Inclusion Criteria:\n\n* positive genetic test for SCA7.\n\nExclusion Criteria:\n\n* cardiac arrhythmias;\n* haematologic diseases;\n* hepatic diseases with serum values of alanine aminotransferase, aspartate aminotransferase or bilirubin \\> 1·5 times above normal limit;\n* pregnancy (women of childbearing potential agreed to use contraception);\n* breastfeeding.","7 Years",{"count":82,"type":20},34,[58,84],"PHASE3","Spinocerebellar ataxia type 7 (SCA7) belongs to the dominant forms of inherited cerebellar ataxias (CA), being one of the rarest form. SCA7 has no therapeutic options, so that the relentless course, the important visual deficit that accompanies CA, and the possibility of disease development in childhood are pressing unmet needs. The investigators published encouraging data on riluzole in inherited CA other than SCA7. These results prompted off-label use of riluzole in single cases of SCA7 in Italy and United States, suggesting possible efficacy of the drug in this condition.",[87],"SCA7",{"date":89,"type":39},"2024-12-02",{"date":91,"type":39},"2021-06-01",{"date":93,"type":20},"2026-09-01",{"name":45,"class":46},""]